Back to Search Start Over

Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study.

Authors :
Huang, Zhuoying
Xu, Shuangfei
Liu, Jiechen
Wu, Linlin
Qiu, Jing
Wang, Nan
Ren, Jia
Li, Zhi
Guo, Xiang
Tao, Fangfang
Chen, Jian
Lu, Donglei
Wang, Yuheng
Li, Juan
Sun, Xiaodong
Wang, Weibing
Source :
Nature Communications; 4/10/2023, Vol. 14 Issue 1, p1-12, 12p
Publication Year :
2023

Abstract

We conducted a matched retrospective cohort study of two cohorts to estimate inactivated vaccine effectiveness (VE) and its comparative effectiveness of booster dose among older people in Shanghai. Cohort 1 consisted of a vaccinated group (≥1 dose) and an unvaccinated group (3,317,475 pairs), and cohort 2 consisted of a booster vaccinated group and a fully vaccinated group (2,084,721 pairs). The Kaplan–Meier method and Cox regression models were used to estimate risk and hazard ratios (HRs) study outcomes. For cohort 1, the overall estimated VEs of ≥1 dose of inactivated vaccine against SARS-CoV-2 infection, severe/critical Covid-19, and Covid-19 related death were 24.7% (95%CI 23.7%−25.7%), 86.6% (83.1%−89.4%), and 93.2% (88.0%−96.1%), respectively. Subset analysis showed that the booster vaccination provided greatest protection. For cohort 2, compared with full vaccination, relative VEs of booster dose against corresponding outcome were 16.3% (14.4%−17.9%), 60.5% (37.8%−74.9%), and 81.7% (17.5%−95.9%). Here we show, although under the scenario of persistent dynamic zero-Covid policy and non-pharmaceutical interventions, promoting high uptake of the full vaccination series and booster dose among older adults is critically important. Timely vaccination with the booster dose provided effective protection against Covid-19 outcomes. Inactivated COVID-19 vaccines have been widely used in China, but there is limited real-world evidence for their effectiveness in this setting. Here, the authors estimate effectiveness of inactivated vaccines for people aged 60 or older in Shanghai during a period when Omicron was the dominant circulating variant. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20411723
Volume :
14
Issue :
1
Database :
Complementary Index
Journal :
Nature Communications
Publication Type :
Academic Journal
Accession number :
162992305
Full Text :
https://doi.org/10.1038/s41467-023-37673-9